Fibroblast growth factor 21

From pharmacology to physiology

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Fibroblast growth factor 21 (FGF21) is an atypical member of the FGF family that functions as an endocrine hormone. Pharmacologic studies showthat FGF21 has broad metabolic actions in obese rodents and primates that include enhancing insulin sensitivity, decreasing triglyceride concentrations, and causing weight loss. In lean rodents, FGF21 expression is strongly induced in liver by prolonged fasting through a mechanism that involves the nuclear receptor peroxisome proliferator-activated receptor α. FGF21, in turn, induces the transcriptional coactivator protein peroxisome proliferator-activated receptor γ coactivator protein 1α and stimulates hepatic gluconeogenesis, fatty acid oxidation, and ketogenesis. FGF21 also blocks somatic growth and sensitizes mice to a hibernation-like state of torpor. Thus, FGF21 plays a key role in eliciting and coordinating the adaptive starvation response. Interestingly, FGF21 expression is induced in white adipose tissue by peroxisome proliferator-activated receptor γ, which suggests that it also regulates metabolism in the fed state. This article highlights recent advances in our understanding of FGF21's pharmacologic and physiologic actions.

Original languageEnglish (US)
JournalAmerican Journal of Clinical Nutrition
Volume91
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Pharmacology
Peroxisome Proliferator-Activated Receptors
Rodentia
Torpor
Pharmacologic Actions
Hibernation
White Adipose Tissue
Gluconeogenesis
fibroblast growth factor 21
Liver
Cytoplasmic and Nuclear Receptors
Starvation
Primates
Insulin Resistance
Weight Loss
Fasting
Triglycerides
Proteins
Fatty Acids
Hormones

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Medicine(all)

Cite this

@article{6251f23544204d7e95d62b7f4c5ac8ef,
title = "Fibroblast growth factor 21: From pharmacology to physiology",
abstract = "Fibroblast growth factor 21 (FGF21) is an atypical member of the FGF family that functions as an endocrine hormone. Pharmacologic studies showthat FGF21 has broad metabolic actions in obese rodents and primates that include enhancing insulin sensitivity, decreasing triglyceride concentrations, and causing weight loss. In lean rodents, FGF21 expression is strongly induced in liver by prolonged fasting through a mechanism that involves the nuclear receptor peroxisome proliferator-activated receptor α. FGF21, in turn, induces the transcriptional coactivator protein peroxisome proliferator-activated receptor γ coactivator protein 1α and stimulates hepatic gluconeogenesis, fatty acid oxidation, and ketogenesis. FGF21 also blocks somatic growth and sensitizes mice to a hibernation-like state of torpor. Thus, FGF21 plays a key role in eliciting and coordinating the adaptive starvation response. Interestingly, FGF21 expression is induced in white adipose tissue by peroxisome proliferator-activated receptor γ, which suggests that it also regulates metabolism in the fed state. This article highlights recent advances in our understanding of FGF21's pharmacologic and physiologic actions.",
author = "Kliewer, {Steven A.} and Mangelsdorf, {David J.}",
year = "2010",
month = "1",
day = "1",
doi = "10.3945/ajcn.2009.28449B",
language = "English (US)",
volume = "91",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "1",

}

TY - JOUR

T1 - Fibroblast growth factor 21

T2 - From pharmacology to physiology

AU - Kliewer, Steven A.

AU - Mangelsdorf, David J.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Fibroblast growth factor 21 (FGF21) is an atypical member of the FGF family that functions as an endocrine hormone. Pharmacologic studies showthat FGF21 has broad metabolic actions in obese rodents and primates that include enhancing insulin sensitivity, decreasing triglyceride concentrations, and causing weight loss. In lean rodents, FGF21 expression is strongly induced in liver by prolonged fasting through a mechanism that involves the nuclear receptor peroxisome proliferator-activated receptor α. FGF21, in turn, induces the transcriptional coactivator protein peroxisome proliferator-activated receptor γ coactivator protein 1α and stimulates hepatic gluconeogenesis, fatty acid oxidation, and ketogenesis. FGF21 also blocks somatic growth and sensitizes mice to a hibernation-like state of torpor. Thus, FGF21 plays a key role in eliciting and coordinating the adaptive starvation response. Interestingly, FGF21 expression is induced in white adipose tissue by peroxisome proliferator-activated receptor γ, which suggests that it also regulates metabolism in the fed state. This article highlights recent advances in our understanding of FGF21's pharmacologic and physiologic actions.

AB - Fibroblast growth factor 21 (FGF21) is an atypical member of the FGF family that functions as an endocrine hormone. Pharmacologic studies showthat FGF21 has broad metabolic actions in obese rodents and primates that include enhancing insulin sensitivity, decreasing triglyceride concentrations, and causing weight loss. In lean rodents, FGF21 expression is strongly induced in liver by prolonged fasting through a mechanism that involves the nuclear receptor peroxisome proliferator-activated receptor α. FGF21, in turn, induces the transcriptional coactivator protein peroxisome proliferator-activated receptor γ coactivator protein 1α and stimulates hepatic gluconeogenesis, fatty acid oxidation, and ketogenesis. FGF21 also blocks somatic growth and sensitizes mice to a hibernation-like state of torpor. Thus, FGF21 plays a key role in eliciting and coordinating the adaptive starvation response. Interestingly, FGF21 expression is induced in white adipose tissue by peroxisome proliferator-activated receptor γ, which suggests that it also regulates metabolism in the fed state. This article highlights recent advances in our understanding of FGF21's pharmacologic and physiologic actions.

UR - http://www.scopus.com/inward/record.url?scp=74049108945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049108945&partnerID=8YFLogxK

U2 - 10.3945/ajcn.2009.28449B

DO - 10.3945/ajcn.2009.28449B

M3 - Article

VL - 91

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

SN - 0002-9165

IS - 1

ER -